The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Hereditary coproporphyria (HCP) is a disorder of heme biosynthesis, classified as an acute hepatic porphyria. HCP is caused by a deficiency of the enzyme coproporphyrinogen oxidase, coded for by the CPOX gene, and is inherited in an autosomal dominant fashion, although homozygous individuals have been identified. Unlike acute intermittent porphyria, individuals with HCP can present with cutaneous findings similar to those found in porphyria cutanea tarda in addition to the acute attacks of abdominal pain, vomiting and neurological dysfunction characteristic of acute porphyrias. Like other porphyrias, attacks of HCP can be induced by certain drugs, environmental stressors or diet changes. Biochemical and molecular testing can be used to narrow down the diagnosis of a porphyria and identify the specific genetic defect. Overall, porphyrias are rare diseases. The combined incidence for all forms of the disease has been estimated at 1:20,000. The exact incidence of HCP is difficult to determine, due to its reduced penetrance.
gene product Any of the biochemical material resulting from the expression of a gene, most commonly interpreted as the functional mRNA transcript produced by transcription of the gene or the fully constructed protein produced by translation of the transcript, though non-coding RNA molecules such as transfer RNAs may also be considered gene products. A measurement of the quantity of a given gene product that is detectable in a cell or tissue is sometimes used to infer how active the corresponding gene is.
In contrast with terrestrial biology, early laboratory studies, including the famous Miller-Urey Experiment, have shown that amino acids may form under a range of possible abiotic conditions with equal (racemic) mixtures of D- and L-enantiomers. Thus, the ratios between enantiomers for a given amino acid may discriminate between biotic and abiotic formation mechanisms. In the first characterisation of amino acids in Murchison, all chiral examples were present in racemic mixtures indicating an abiotic origin. This is consistent with proposed sythetic pathways, as the formation of isovaline and other α-dialkyl amino acids in CM chondrites has been attributed to the Strecker synthesis which produces racemic mixtures of enantiomers.
=== Sample introduction === The first step in analysis is the introduction of the sample. This has been achieved in ICP-MS through a variety of means. The most common method is the use of analytical nebulizers. A nebulizer converts liquids into an aerosol, and that aerosol can then be swept into the plasma to create the ions. Nebulizers work best with simple liquid samples (i.e. solutions). However, there have been instances of their use with more complex materials like a slurry. Many varieties of nebulizers have been coupled to ICP-MS, including pneumatic, cross-flow, Babington, ultrasonic, and desolvating types. The aerosol generated is often treated to limit it to only smallest droplets, commonly by means of a Peltier cooled double pass or cyclonic spray chamber. Use of autosamplers makes this easier and faster, especially for routine work and large numbers of samples. A Desolvating Nebuliser (DSN) may also be used; this uses a long heated capillary, coated with a fluoropolymer membrane, to remove most of the solvent and reduce the load on the plasma. Matrix removal introduction systems are sometimes used for samples, such as seawater, where the species of interest are at trace levels, and are surrounded by much more abundant contaminants. Laser ablation is another method. Though less common in the past, it has become popular as a means of sample introduction, thanks to increased ICP-MS scanning speeds. In this method, a pulsed UV laser is focused on the sample and creates a plume of ablated material, which can be swept into the plasma.
Sources: en.wikipedia.org
==== Hypoglycemia ==== An acute hypoglycemic episode (very low blood sugar) can happen to even careful pet owners, since cats' insulin requirements sometimes change without warning. The symptoms include depression/lethargy, confusion/dizziness, loss of excretory/bladder control, vomiting, and then loss of consciousness and/or seizures. Immediate treatment includes administering honey or corn syrup by rubbing on the gums of the cat (even if unconscious, but not if in seizures). Symptomatic hypoglycemia in cats is a medical emergency and the cat will require professional medical attention. The honey/corn syrup should continue to be administered on the way to the vet, as every minute without blood sugar causes brain damage. A cat with hypoglycemia according to a human-calibrated blood glucose meter (<2.2 mmol/L or 40 mg/dL), but with no symptoms, should be fed as soon as possible. Hypoglycemic cats that refuse to eat can be force-fed honey or corn syrup until they stabilize, though this may not be done if the animal is unconscious or having a seizure, as the liquid is likely to enter the animal's lungs and cause choking and asphyxiation. Mild hypoglycemic episodes can go unnoticed or leave evidence such as urine pools outside the litter box. In these cases the blood sugar will probably appear paradoxically high upon the next test hours later, since the cat's body will react to the low blood sugar by stimulating the liver to release stored glycogen.
The museum's collection consists of hundreds of thousands of items intended for daily life on the frontier including more than 4,000 boots and shoes, 247 hats, 235 ax heads, 29 jars of pickles, 328 pocket knives, and one children's doll. All are from 1856 or earlier; most of them were brand-new merchandise heading to general stores on the frontier. The Wall Street Journal called it "an Aladdin's cave of objects from the year 1856".
== Background == The incident occurred at a time of severely strained relations between the United States and the Soviet Union. Responding to the Soviet Union's deployment of fourteen SS-20/RSD-10 theatre nuclear missiles, the NATO Double-Track Decision was taken in December 1979 by the military commander of NATO to deploy 108 Pershing II nuclear missiles in Western Europe with the ability to hit targets in eastern Ukraine, Belarus or Lithuania within 10 minutes and the longer range, but slower BGM-109G Ground Launched Cruise Missile (GLCM) to strike potential targets farther to the east. In mid-February 1981, and continuing until 1983, psychological operations by the United States began. These were designed to test Soviet radar vulnerability and to demonstrate US nuclear capabilities. They included clandestine naval operations in the Barents, Norwegian, Black and Baltic Sea and near the GIUK gap, as well as flights by American bombers, occasionally several times per week, directly toward Soviet airspace that turned away only at the last moment.
In both males and females, FSH stimulates the maturation of primordial germ cells. In males, FSH induces Sertoli cells to secrete androgen-binding proteins (ABPs), regulated by inhibin's negative feedback mechanism on the anterior pituitary. Specifically, activation of Sertoli cells by FSH sustains spermatogenesis and stimulates inhibin B secretion. In females, FSH initiates follicular growth, specifically affecting granulosa cells. With the concomitant rise in inhibin B, FSH levels then decline in the late follicular phase. This seems to be critical in selecting only the most advanced follicle to proceed to ovulation. At the end of the luteal phase, there is a slight rise in FSH that seems to be of importance to start the next ovulatory cycle. Control of FSH release from the pituitary gland is unknown. Low frequency gonadotropin-releasing hormone (GnRH) pulses increase FSH mRNA levels in the rat, but is not directly correlated with an increase in circulating FSH. GnRH has been shown to play an important role in the secretion of FSH, with hypothalamic–pituitary disconnection leading to a cessation of FSH. GnRH administration leads to a return of FSH secretion. FSH is subject to oestrogen feed-back from the gonads via the hypothalamic pituitary gonadal axis.
== TNF inhibitors == TNF inhibitors are commonly the first drug prescribed when a patient begins biologic therapy. They have the most extensive history of clinical evidence because they have been available the longest, are the most accessible, and are often the least expensive. Initially, it was thought that TNF inhibitors inactivate the proinflammatory cytokine by direct neutralization, but TNF signaling is a very complex process. Many recent studies suggest that TNF inhibitors may act with a more complex mechanism than simple blockade. They are all administered systemically either subcutaneously or intravenously.
Sources: en.wikipedia.org
== Biosynthesis and regulation == Calcitonin is formed by the proteolytic cleavage of a larger prepropeptide, which is the product of the CALC1 gene (CALCA). It is functionally an antagonist with PTH and Vitamin D3. The CALC1 gene belongs to a superfamily of related protein hormone precursors including islet amyloid precursor protein, calcitonin gene-related peptide, and the precursor of adrenomedullin. Secretion of calcitonin is stimulated by:
=== Pharmacokinetics === Paroxetine is well-absorbed following oral administration. It has an absolute bioavailability of about 50%, with evidence of a saturable first pass effect. When taken orally, it achieves maximum concentration in about 6–10 hours and reaches steady-state in 7–14 days. Paroxetine exhibits significant interindividual variations in volume of distribution and clearance. Less than 2% of an oral dose is excreted in urine unchanged. Paroxetine is a mechanism-based inhibitor of CYP2D6.
=== Pharmacokinetics === Temozolomide is quickly and almost completely absorbed from the gut, and readily penetrates the blood–brain barrier; the concentration in the cerebrospinal fluid is 30% of the concentration in the blood plasma. Intake with food decreases maximal plasma concentrations by 33% and the area under the curve by 9%. Only 15% (10–20%) of the substance are bound to blood plasma proteins. Temozolomide is a prodrug; at physiological pH, it is spontaneously hydrolyzed to 5-(3-methyl-triazen-1-yl)imidazole-4-carboxamide (MTIC), which undergoes further hydrolysis to methyldiazonium, likely the active methylating agent, and 5-aminoimidazole-4-carboxamide (AIC). Other metabolites include temozolomide acid and unidentified hydrophilic substances. Plasma half-life is 1.8 hours. The substance and its metabolites are mainly excreted via the urine.
The report argued that the UK's top-down strategy is driving vast increases in mineral demands with devastating impacts for mining-affected communities, and called for policies geared towards minimising the UK's overall mineral demands and tackling the impunity of British-listed mining corporations. Similarly, the Centre for International Governance Innovation (CIGI) has warned that the infrastructure of AI exposes a host of hidden environmental security issues, requiring international cooperation that accounts for sustainability and labour standards.
Oxandrolone is an androgen and synthetic anabolic steroid (AAS) medication to help promote weight gain in various situations, to help offset protein catabolism caused by long-term corticosteroid therapy, to support recovery from severe burns, to treat bone pain associated with osteoporosis, to aid in the development of girls with Turner syndrome, and for other indications. It is taken by mouth. It was sold under the brand names Oxandrin and Anavar, among others. The drug is a synthetic androgen and anabolic steroid, hence is an agonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone. Side effects of oxandrolone include severe cases of peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver tumors, sometimes fatal; and blood lipid changes associated with increased risk of atherosclerosis. Additional warnings include the risks associated with cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in older patients. It has strong anabolic effects and weak androgenic effects, which gave it a mild side effect profile in that regard and made it especially suitable for use in women. Milder side effects in women were increased sexual desire, symptoms of hyperandrogenism such as acne, and symptoms of masculinization such as increased hair growth and voice changes. Oxandrolone was first described in 1962 and introduced for medical use in 1964.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.